• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

掌腱膜挛缩症治疗后的并发症。一项系统的文献综述。

Complications after treating Dupuytren's disease. A systematic literature review.

作者信息

Krefter C, Marks M, Hensler S, Herren D B, Calcagni M

机构信息

Department of Hand Surgery, Schulthess Klinik, Lengghalde 2, 8008 Zurich, Switzerland.

Department of Teaching, Research and Development, Schulthess Klinik, Lengghalde 2, 8008 Zurich, Switzerland.

出版信息

Hand Surg Rehabil. 2017 Oct;36(5):322-329. doi: 10.1016/j.hansur.2017.07.002. Epub 2017 Sep 14.

DOI:10.1016/j.hansur.2017.07.002
PMID:28917432
Abstract

The objective of this study was to review the incidence of complications associated with different treatment options for patients with Dupuytren's disease. In a systematic literature review, the PubMed, EMBASE, Cochrane and Scopus databases were searched for clinical studies reporting complications after collagenase treatment, percutaneous needle fasciotomy (PNF), fasciectomy and dermofasciectomy. The incidence of complications was extracted from each study and stratified by procedure. From a total of 2251 references, 113 studies were analyzed and included with complication incidences varying from 0% to 100%. The highest number of nerve and vessel lesions were reported after fasciectomy, whereas the highest rate of edema was after collagenase injection. Accidental skin tears were mostly associated with collagenase and PNF treatment. Pooled complication incidences were 17.4% (95% CI: 11.7-23.1) for fasciectomy, 78.0% (95% CI: 59.6-96.4) for collagenase treatment, 18.9% (95% CI: -5.5-43.3) for PNF and 11.6% (95% CI: 0.0-23.2) for dermofasciectomy. Due to inconsistencies in reporting complications as well as the lack of a standardized definition, the literature does not provide evidence in favor of a specific procedure for Dupuytren's disease. A standardized definition of complications is required to improve the comparability of published results.

摘要

本研究的目的是回顾与杜普伊特伦挛缩症患者不同治疗方案相关的并发症发生率。在一项系统的文献综述中,检索了PubMed、EMBASE、Cochrane和Scopus数据库,以查找报告胶原酶治疗、经皮针状筋膜切开术(PNF)、筋膜切除术和皮肤筋膜切除术术后并发症的临床研究。从每项研究中提取并发症发生率,并按手术方式进行分层。在总共2251篇参考文献中,分析并纳入了113项研究,并发症发生率从0%到100%不等。筋膜切除术后报告的神经和血管损伤数量最多,而胶原酶注射后水肿发生率最高。意外皮肤撕裂大多与胶原酶和PNF治疗有关。筋膜切除术的合并并发症发生率为17.4%(95%CI:11.7-23.1),胶原酶治疗为78.0%(95%CI:59.6-96.4),PNF为18.9%(95%CI:-5.5-43.3),皮肤筋膜切除术为11.6%(95%CI:0.0-23.2)。由于并发症报告存在不一致性以及缺乏标准化定义,文献中没有提供支持杜普伊特伦挛缩症特定手术方式的证据。需要对并发症进行标准化定义,以提高已发表结果的可比性。

相似文献

1
Complications after treating Dupuytren's disease. A systematic literature review.掌腱膜挛缩症治疗后的并发症。一项系统的文献综述。
Hand Surg Rehabil. 2017 Oct;36(5):322-329. doi: 10.1016/j.hansur.2017.07.002. Epub 2017 Sep 14.
2
Efficacy and adverse effects of collagenase use in the treatment of Dupuytren's disease: a meta-analysis.胶原酶用于治疗掌腱膜挛缩症的疗效与不良反应:一项荟萃分析。
Bone Joint J. 2018 Jan;100-B(1):73-80. doi: 10.1302/0301-620X.100B1.BJJ-2017-0463.R1.
3
Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症:系统评价与经济学评估
Health Technol Assess. 2015 Oct;19(90):1-202. doi: 10.3310/hta19900.
4
Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up.胶原酶注射与经皮针刀松解治疗掌腱膜挛缩症的疗效比较:3 年随访的客观和主观比较。
Plast Reconstr Surg. 2020 Jun;145(6):1464-1474. doi: 10.1097/PRS.0000000000006828.
5
Cost Comparison of Collagenase Clostridium Histolyticum and Fasciectomy for Treatment of Dupuytren's Contracture in the Australian Health System.澳大利亚医疗体系中溶组织梭状芽孢杆菌胶原酶与筋膜切除术治疗掌腱膜挛缩症的成本比较
J Hand Surg Asian Pac Vol. 2018 Sep;23(3):336-341. doi: 10.1142/S2424835518500327.
6
Dupuytren's contracture: an analysis of outcomes of percutaneous needle fasciotomy versus open fasciectomy.杜普伊特伦挛缩症:经皮针状筋膜切开术与开放性筋膜切除术的疗效分析
ANZ J Surg. 2015 Sep;85(9):639-43. doi: 10.1111/ans.12513. Epub 2014 Jan 20.
7
Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren's contracture: a network meta-analysis of randomized controlled trials.胶原酶注射、经皮针刀松解和有限筋膜切开术治疗掌腱膜挛缩的短期疗效和不良反应:一项随机对照试验的网络荟萃分析。
BMC Musculoskelet Disord. 2022 Oct 28;23(1):939. doi: 10.1186/s12891-022-05894-6.
8
A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren's contracture of the hand.手部挛缩性杜普伊特伦氏病中胶原酶注射与手术筋膜切开术的单中心成本比较分析。
J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):368-72. doi: 10.1016/j.bjps.2013.12.030. Epub 2014 Jan 4.
9
Systematic Review Comparing Cost Analyses of Fasciectomy, Needle Aponeurotomy, and Collagenase Injection for Treatment of Dupuytren's Contracture: Une analyse de coûts systématique comparant la fasciectomie, l'aponévrotomie percutanée à l'aiguille et l'injection de collagénase pou traiter la maladie de Dupuytren.比较筋膜切除术、经皮针腱膜切开术和胶原酶注射治疗掌腱膜挛缩症成本分析的系统评价:一项比较筋膜切除术、经皮针腱膜切开术和胶原酶注射治疗掌腱膜挛缩症的成本系统分析。
Plast Surg (Oakv). 2021 Nov;29(4):257-264. doi: 10.1177/2292550320963111. Epub 2020 Oct 16.
10
Treatment of Dupuytren's contracture: a systematic review.掌腱膜挛缩症的治疗:系统评价。
Bone Joint J. 2018 Sep;100-B(9):1138-1145. doi: 10.1302/0301-620X.100B9.BJJ-2017-1194.R2.

引用本文的文献

1
Active synthesis of type I collagen homotrimer in Dupuytren's fibrosis is unaffected by anti-TNF-α treatment.在杜普伊特伦挛缩症纤维化中,I型胶原同三聚体的活性合成不受抗TNF-α治疗的影响。
JCI Insight. 2025 May 8;10(9). doi: 10.1172/jci.insight.175188.
2
Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation.英国成年患者中胶原酶注射与有限筋膜切除术治疗掌腱膜挛缩症的比较:DISC,一项非劣效性随机对照试验及经济学评估
Health Technol Assess. 2024 Dec;28(78):1-262. doi: 10.3310/KGXD8528.
3
Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture.
胶原酶注射与有限掌腱膜切除术治疗Dupuytren 挛缩。
N Engl J Med. 2024 Oct 24;391(16):1499-1510. doi: 10.1056/NEJMoa2312631. Epub 2024 Oct 9.
4
Bias in published randomized trials that compare collagenase injection with percutaneous needle fasciotomy in the treatment of Dupuytren disease: a systematic review.比较胶原酶注射与经皮针状筋膜切开术治疗掌腱膜挛缩症的已发表随机试验中的偏倚:一项系统评价
EFORT Open Rev. 2024 Jul 1;9(7):625-631. doi: 10.1530/EOR-23-0211.
5
Dupuytren's Disease: A Novel Minimally Invasive Pull-Through Technique.杜普伊特伦挛缩症:一种新型微创拖出技术
Arch Plast Surg. 2024 Mar 4;51(3):295-303. doi: 10.1055/s-0043-1775882. eCollection 2024 May.
6
Delayed vascular complication after collagenase injection for Dupuytren disease.胶原酶注射治疗杜普伊特伦挛缩症后的血管并发症延迟发生。
BMC Musculoskelet Disord. 2023 Oct 23;24(1):837. doi: 10.1186/s12891-023-06964-z.
7
Treatments for early-stage Dupuytren's disease: an evidence-based approach.早期掌腱膜挛缩症的治疗:循证方法。
J Hand Surg Eur Vol. 2023 Mar;48(3):191-198. doi: 10.1177/17531934221131373. Epub 2023 Jan 13.
8
Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren's contracture: a network meta-analysis of randomized controlled trials.胶原酶注射、经皮针刀松解和有限筋膜切开术治疗掌腱膜挛缩的短期疗效和不良反应:一项随机对照试验的网络荟萃分析。
BMC Musculoskelet Disord. 2022 Oct 28;23(1):939. doi: 10.1186/s12891-022-05894-6.
9
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.抗肿瘤坏死因子疗法治疗早期杜普伊特伦挛缩病(RIDD):一项2b期随机双盲安慰剂对照试验
Lancet Rheumatol. 2022 Jun;4(6):E407-E416. doi: 10.1016/S2665-9913(22)00093-5. Epub 2022 Apr 29.
10
A Personalized Approach to Treat Advanced Stage Severely Contracted Joints in Dupuytren's Disease with a Unique Skeletal Distraction Device-Utilizing Modern Imaging Tools to Enhance Safety for the Patient.一种采用独特骨骼牵张装置治疗杜普伊特伦挛缩症晚期严重挛缩关节的个性化方法——利用现代成像工具提高患者安全性。
J Pers Med. 2022 Mar 1;12(3):378. doi: 10.3390/jpm12030378.